Company intelligence / Profile preview
Marizyme
Jupiter, Florida, United Statesmarizyme.com ↗
- Ownership
- Public · MRZM
- Employees
- ~13
- Development stage
- Commercial
01
Overview
Marizyme’s DuraGraft solution for vascular graft preservation has received De Novo FDA clearance and CE marking. The Krillase-derived MB101 wound debridement product has been tested in over a dozen Phase II studies in Europe with more than 500 patients. Other pipeline programs remain at preclinical or early clinical stages.
- Therapeutic areas
- NephrologyOtherDermatologyCardiovascularNeurology
- Modalities
- Recombinant proteaseProteinDevice
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Financials
- Market cap
- $39.5K
- Total revenue
- $645.8K
- Enterprise value
- $26.6M
Beyond the preview
Go deeper on Marizyme.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Marizyme.